How Biotech Startups Use Microbiome Engineering to Treat Disease

In this episode of Biotech Business with Fexingo, Lucas and Luna explore how biotech startups are engineering the human microbiome to treat chronic diseases. They focus on the case of Synlogic, a company that developed a genetically engineered probiotic to treat phenylketonuria (PKU), a rare genetic disorder. The discussion covers how Synlogic's approach works, the challenges of using living therapeutics, and why big pharma is investing in microbiome startups. Lucas explains the science behind engineering bacteria to break down toxic metabolites, while Luna questions the regulatory hurdles and scalability. The episode also touches on the broader trend of microbiome engineering for metabolic and inflammatory diseases, with specific numbers on market growth and clinical trial results. A concrete look at how synthetic biology is turning gut bacteria into programmable medicines. #MicrobiomeEngineering #Synlogic #ProbioticTherapeutics #PKU #SyntheticBiology #LivingTherapeutics #GutBacteria #MetabolicDisease #BiotechStartup #DrugDiscovery #FDAApprovals #ClinicalTrials #RareDisease #GeneEditing #Business #Technology #FexingoBusiness #BusinessPodcast Keep every episode free: buymeacoffee.com/fexingo